Full-Time

Associate Director of Clinical Development Immunology

Posted on 5/12/2026

Deadline 5/15/26
Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$123k - $180.4k/yr

+ Bonus

No H1B Sponsorship

Indianapolis, IN, USA

In Person

Must be authorized to work in the United States; no visa sponsorship provided.

Category
Biology & Biotech (1)
Required Skills
Risk Management
Requirements
  • Bachelor's degree, preferably in a scientific or health-related field
  • 5+ years in the pharmaceutical industry and/or clinical development
  • 5+ years project management experience across the clinical trial landscape
  • 3+ years managing a team of direct reports virtually and across geographies/cultures
  • Experience managing clinical development processes and associate tasks
  • Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.
Responsibilities
  • Responsible for clinical development of the assigned compound and/or indication from asset strategy through submission, inspection, approval and post-launch support.
  • Collaborates with the Senior Director/Executive Director Clinical Development, Asset Team and Clinical Design to accelerate execution of the complete trial package (scope, timeline, budget and risk management).
  • Lead the global clinical submission strategy, including scope, timeline, resource and risk management.
  • Ensures collaboration with Clinical Design and Clinical Development Trial Lead (CDTL) and other cross-functional MDU team members for effective transition of clinical trial package to execution and clinical delivery.
  • Responsible for execution and delivery of the global clinical submission plan, including communications to team and leadership, resource and risk management.
  • Responsible for executing clinical plan/trial to the approved timeline; ability to understand the critical chain methodology and use its functionality to manage program/trial; ability to make updates to the critical chain.
  • Manages risks plans at the indication/trial-level during the implementation in response to new data and changes in the environment.
  • Responsible for budget planning, monitoring and control of the total trial budget at the compound and or indication-level; works closely with the CDTLs who are responsible for the trial-level grants and nongrants budgets and rolls-up budget information to Senior Director/Executive Director Clinical Development who is accountable for the total clinical plan budget.
  • Responsible for completing the clinical assumptions within the UAT (unified assumptions tracker), attending financial meetings, and ensuring that the total trial budgets are accurate.
  • Manages global cross-functional communication and escalations to ensure alignment on delivery and execution.
  • Utilizes regulatory and process knowledge to drive decision making.
  • Establishing and managing partner expectations, performance and delivery (i.e. CRO, Alliances and Joint Ventures).
  • Align cross-functional resources based on portfolio prioritization inclusive of being flexible across therapeutic areas.
  • Ensure Clinical Development Trial Lead Competencies evolve and address implications to overall resource management and strategies.
  • Maintains a state of inspection readiness for clinical development inclusive of the Trial Master File (TMF).
  • Models judgement-based decision-making to navigate compliance and quality requirements.
  • Responsible for continuous improvement in the following: clinical development, complete trial packages from the Clinical Design and process improvements to process owners in the spirit of streamlining the efficiency and effectiveness of conducting clinical trials and non-trial work.
  • Recruit, develop and retain a diverse and highly capable workforce
  • Build an organizational culture that fosters inclusion
  • Support and encourage talent identification, development and retention that reflects an end-to-end process mindset and demonstrates judgement-based decision making.
  • Ensure robust training plan and timely completion of required training for direct reports.
Desired Qualifications
  • Project Management certification (e.g., PMP)
  • Previous supervisory experience
  • Proven ability to coach and develop others
  • Prior experience in working with a non-Lilly business partner (e.g., CRO, Alliance, Joint Venture)
  • Prior submission and inspection experience
  • Prior experience with the management of business plans
  • Ability to embrace the diversity of thought to model innovative behaviors (e.g. reaching across boundaries, inspire and empower others and lead decisively in the midst of ambiguity)
  • Strong self-management and organizational skills; able to manage workload, set personal and team priorities and adjust as needed
  • Able to influence others without direct authority
  • Strong problem-solving skills; able to anticipate and recognize systemic problems, diagnose root causes and take corrective actions to prevent reoccurrence
  • Travel may be required

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • International Mounjaro sales jumped to $4.4 billion in Q1 from China's reimbursement list.
  • $4.5 billion Lebanon API plant opens 2027, producing tirzepatide and retatrutide at largest scale.
  • Acquires Scorpion's PI3Kα inhibitor, bolstering oncology pipeline beyond Verzenio.

What critics are saying

  • Novo Nordisk's Wegovy scaling erodes Lilly's US GLP-1 share below 25% into 2027.
  • FDA scrutiny delays Foundayo launch after May 4 hepatic failure, losing $2-3B Q4 revenue.
  • Shareholder demands force independent board chair, dropping stock 10-15% in 12 months.

What makes Lilly USA unique

  • Mounjaro generated $8.66 billion in Q1 2026 sales, surpassing Keytruda as world's best-selling drug.
  • Launched first genetic medicine facility in Lebanon on May 6, 2026, for Alzheimer's and ALS.
  • Partnered with Profluent Bio for up to $2.25 billion AI-driven DNA editing tools on May 5.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lilly USA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.